Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

2.89
+0.10003.58%
Post-market: 2.920.0259+0.90%19:30 EDT
Volume:359.31K
Turnover:1.00M
Market Cap:208.69M
PE:-1.77
High:2.90
Open:2.77
Low:2.69
Close:2.79
52wk High:3.60
52wk Low:1.21
Shares:72.21M
Float Shares:37.05M
Volume Ratio:0.94
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6370
EPS(LYR):-2.0035
ROE:-120.50%
ROA:-45.77%
PB:3.64
PE(LYR):-1.44

Loading ...

Acumen Pharmaceuticals is Maintained at Buy by Citigroup

Dow Jones
·
11 hours ago

Citi ups Acumen target, opens ‘upside 90-day catalyst watch’

TIPRANKS
·
Yesterday

Acumen Pharmaceuticals Announces Virtual Investor Day Meeting

Reuters
·
Sep 11

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 03

ProMIS Neurosciences Q2 Net Loss Widens

Reuters
·
Aug 14

Citi Remains a Buy on Acumen Pharmaceuticals (ABOS)

TIPRANKS
·
Aug 13

Acumen Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Acumen Pharmaceuticals Posts Corporate Presentation on Sabirnetug Antibody Program for Early Alzheimer’s Disease

Reuters
·
Aug 12

Acumen Pharmaceuticals Q2 EPS $(0.45) Misses $(0.34) Estimate

Benzinga Earnings
·
Aug 12

Acumen Pharmaceuticals Q2 Net Loss Widens, Misses Analyst Estimates

Reuters
·
Aug 12

Acumen Pharmaceuticals, Inc. Q2 Income from Operations USD -32.556 Million Vs. IBES Estimate USD -24.6 Million

Reuters
·
Aug 12

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

THOMSON REUTERS
·
Aug 12

Acumen Pharmaceuticals, Inc. Q2 Basic EPS USD -0.45

THOMSON REUTERS
·
Aug 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 11

Acumen Pharmaceuticals Inc Expected to Post a Loss of 37 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Acumen Pharmaceuticals Inc Expected to Post a Loss of 37 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

GlobeNewswire
·
Aug 06

Acumen presents new findings at AAIC conference

TIPRANKS
·
Jul 15

Acumen Says EBD Candidate Acu401 Boosts Brain Exposure up to 40-fold in Primate Study

Reuters
·
Jul 15

Acumen Pharmaceuticals - Ebd Bispecific Antibodies Show Improved Brain Penetration Compared to Native Anti-aβo Antibodies

THOMSON REUTERS
·
Jul 15